Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Chola Securities’ Dharmesh Kant bets on banks, power; cautions on consumer valuations
Dharmesh Kant, Head Research at Chola Securities, says India's growth outlook remains strong, driven by robust demand, infrastructure execution and healthy credit growth. He remains positive on power equipment after further correction, prefers select private and PSU banks, sees value in pharma and hospitals, and is constructive on Mumbai-focused real estate. However, he advises caution on richly valued consumer stocks despite improving business fundamentals.
SBI Securities prefers HDFC Bank, sees long-term upside in metals
Sunny Agarwal, Head Fundamental Research, Retail Desk at SBI Securities, remains positive on private banks, preferring HDFC Bank over Kotak Mahindra Bank after the lender received a clean legal review. He says Persistent Systems' acquisition benefits may take up to eight quarters to materialise, while slower growth remains a near-term concern. Agarwal is also bullish on the metals sector, with Indian Metals & Ferro Alloys as his top pick, and remains positive on Astral over the long term despite near-term challenges.
Retail health premium growth rises to 31% YoY in April 2026, anchoring non-life insurance sector: Kotak Institutional Securities
Indian non-life insurance saw robust growth in April 2026. Retail health premiums surged 31 percent year-on-year. Motor insurance also performed well. Private players and standalone health insurers are gaining market share from public sector companies. Commercial lines faced challenges, though marine and engineering segments showed resilience. This indicates a dynamic shift in the insurance landscape.
Sun Pharma a trading play on dips, banks may face difficult June quarter: Dharmesh Kant
Dharmesh Kant, Head of Research at Chola Securities, said Sun Pharma’s all-cash acquisition of Organon could improve return ratios and support valuations, but may bring overall revenue growth down to single digits. He sees a trading opportunity in Sun Pharma on price dips. On banking, he said Q1 could be difficult as provisioning picks up, which may weigh on profitability even as asset quality and margins remain stable. Disclaimer: The views and tips expressed by investment experts on CNBCTV18.com are their own, not of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.
Pharma and healthcare companies to face continued margin pressure: HDFC Securities
The Indian pharmaceutical and healthcare sector is expected to see moderate revenue growth, with EBITDA margins remaining flat, in the March quarter, according to a brokerage report by HDFC Securities. "We project sales/EBITDA growth of 11%/6% YoY for our coverage universe," the brokerage added.
IT stocks may bounce back; pharma growth outlook strong: Elara Securities
Bino Pathiparampil, Head of Research at Elara Securities, says HUL’s recovery depends on the execution of its strategy to tap new-age consumption trends as traditional FMCG growth remains muted. He sees near-term rebound potential in IT stocks after sharp corrections, though AI-led growth may take time to emerge. He adds semaglutide could create a $1 billion opportunity in India’s pharma market over the next four years.